I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as. This study were approved by the Nagasaki International University Ethics Committee (Approval number 50, July 2, 2021).Īll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. The details of the IRB/oversight body that provided approval or exemption for the research described are given below: I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. We have not received any external funding for this research. The authors have declared no competing interest. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG). This information will give impacts on considering adverse events and its mechanisms in mRNA vaccination. The Moderna COVID-19 vaccine (mRNA 1273) was listed for EUL on 30 April 2021 and the Sinopharm COVID-19 vaccine was listed for EUL on. The results of this study clarified for the first time that age less than 20 years is a risk factor for systemic adverse events from the COVID-19 Vaccine Moderna Intramuscular Injection. Local adverse events were associated with sex (female) and allergy history, with odds ratios (ORs) (95% confidence interval ) of 2.15 (1.69-2.73) and 1.73 (1.10-2.74), respectively. The most common adverse event was myalgia (34%).Ī multivariable logistic regression model was used to determine risk factors. Systemic adverse events occurred in 48% of participants. Injection site pain was the most common local adverse event (71%). Departments Clarify Required Coverage of At-Home OTC COVID-19 Tests Where participants, beneficiaries and enrollees live The current utilization of a pharmacy. Clarifying the pathogenesis of COVID-19 and developing new therapeutic. Eighty-two percent of participants complained of local adverse events. The mortality of coronavirus disease 2019 (COVID-19) is strongly correlated with. We analyzed 1,877 data obtained from a questionnaire survey of 1,993 vaccinated individuals. The proportion of participants with adverse events at the vaccination site (immediately or within 30 minutes after vaccination) was 0.5%, and anaphylaxis occurred in one female student (0.03%). A cross-sectional study was conducted to clarify the adverse events of COVID-19 vaccines in Japanese young population.